OverviewSuggest Edit

Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. It provides an antisense technology platform designed to treat complicated and rare diseases. The company offers SPINRAZA, a treatment for children and adults with spinal muscular atrophy (SMA), TEGSEDI, a medicine that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis, and Waylivra, a medicine used to treat familial chylomicronaemia syndrome (FCS).
TypePublic
Founded1989
HQCarlsbad, CA, US
Websiteionispharma.com
Employee Ratings3.7
Overall CultureD

Latest Updates

Employees (est.) (Feb 2021)757(-7%)
Job Openings50
Revenue (FY, 2020)$729.3 M(-35%)
Share Price (Sept 2021)$36.3(-1%)
Cybersecurity ratingAMore

Key People/Management at Ionis Pharmaceuticals

Brett P. Monia

Brett P. Monia

Chief Executive Officer & Director
Onaiza Cadoret-Manier

Onaiza Cadoret-Manier

Executive Vice President, Chief Corporate Development and Commercial Officer
C. Frank Bennett

C. Frank Bennett

Executive Vice President, Chief Scientific Officer
Eric E. Swayze

Eric E. Swayze

Executive Vice President, Research
Patrick R. O'Neil

Patrick R. O'Neil

Executive Vice President, Legal & General Counsel, Chief Compliance Officer
Richard S. Geary

Richard S. Geary

Executive Vice President, Chief Development Officer
Show more

Ionis Pharmaceuticals Office Locations

Ionis Pharmaceuticals has an office in Carlsbad
Carlsbad, CA, US (HQ)
2855 Gazelle Ct
Show all (1)

Ionis Pharmaceuticals Financials and Metrics

Ionis Pharmaceuticals Revenue

Embed Graph
View revenue for all periods
Ionis Pharmaceuticals's revenue was reported to be $729.26 m in FY, 2020 which is a 35% decrease from the previous period.
USD

Revenue (Q1, 2021)

111.6m

Gross profit (Q1, 2021)

109.0m

Gross profit margin (Q1, 2021), %

97.7%

Net income (Q1, 2021)

(89.9m)

EBIT (Q1, 2021)

(92.0m)

Market capitalization (9-Sept-2021)

5.1b

Closing stock price (9-Sept-2021)

36.3

Cash (31-Mar-2021)

414.2m

EV

4.8b
Ionis Pharmaceuticals's current market capitalization is $5.1 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

599.7m1.1b729.3m

Revenue growth, %

87%(35%)

Cost of goods sold

1.8m4.4m11.9m

Gross profit

597.9m1.1b717.3m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

297.2m163.8m167.9m133.4m145.5m160.1m111.6m

Cost of goods sold

1.0m1.4m967.0k2.5m3.0m3.1m2.6m

Gross profit

296.2m162.4m166.9m130.8m142.5m157.0m109.0m

Gross profit Margin, %

100%99%99%98%98%98%98%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

278.8m683.3m397.7m

Accounts Receivable

12.8m63.0m76.2m

Inventories

8.6m18.2m22.0m

Current Assets

2.2b2.7b2.1b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

375.8m272.5m247.9m486.2m530.2m633.1m414.2m

Accounts Receivable

10.5m31.6m49.1m28.6m27.8m39.0m23.4m

Inventories

11.1m18.5m19.4m22.9m23.7m22.2m22.2m

Current Assets

2.4b2.4b2.4b2.6b2.5b2.5b2.0b
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

215.0m303.3m(486.8m)

Depreciation and Amortization

12.5m16.0m17.2m

Inventories

1.4m(5.4m)(1.3m)

Accounts Payable

(655.0k)(16.3m)(2.8m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

90.9m80.9m99.3m(58.5m)(102.2m)(145.3m)(89.9m)

Depreciation and Amortization

3.5m8.2m11.9m4.1m7.4m12.6m4.9m

Inventories

(2.5m)(5.7m)(6.6m)(2.2m)(3.0m)(1.5m)(234.0k)

Accounts Payable

(17.2m)(16.1m)(18.8m)411.0k(14.9m)(11.0m)(9.6m)
USDFY, 2018

EV/EBIT

-127.2 x

EV/CFO

12.9 x

Revenue/Employee

1.1m

Debt/Equity

0.5 x

Debt/Assets

0.2 x

Financial Leverage

2.2 x

P/E Ratio

26.1
Show all financial metrics

Ionis Pharmaceuticals Operating Metrics

FY, 2018FY, 2019FY, 2020Jun, 2021

Patents (US)

161

Phase I Trials Products

746

Phase II Trials Products

141724

Phase III Trials Products

356
Show all operating metrics

Ionis Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
Akcea TherapeuticsAugust 31, 2020$500 m
Akcea Securities Corporation
Akcea Therapeutics Canada Inc
Akcea Therapeutics France SAS
Akcea Therapeutics Germany GmbH
Akcea Therapeutics, Inc
Akcea Therapeutics Ireland Limited
Akcea Therapeutics UK Limited
Ionis Development (Ireland) Limited
Isis USA Limited
Show more

Ionis Pharmaceuticals Revenue Breakdown

Embed Graph

Ionis Pharmaceuticals revenue breakdown by business segment: 80.4% from Ionis Core and 19.6% from Akcea Therapeutics

Ionis Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Ionis Pharmaceuticals Online and Social Media Presence

Embed Graph

Ionis Pharmaceuticals Company Culture

  • Overall Culture

    D

    60/100

  • CEO Rating

    C

    67/100

  • Compensation

    C+

    69/100

  • Diversity

    D

    60/100

Learn more on Comparably

Ionis Pharmaceuticals News and Updates

Ionis Pharmaceuticals : Q2 Earnings Snapshot

Ionis Pharmaceuticals Inc. (IONS) on Wednesday reported a loss of $81 million in its second quarter.

Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc (NASDAQ: BCYC) to increase the delivery capabilities of Ionis' advanced LIgand Conjugated Antisense (LICA) medicines.

Ionis Pharmaceuticals Stock Looks Attractive At $37

We believe that the stock price of Ionis Pharmaceuticals, a biotech company that specializes in discovering and developing RNA-targeted therapeutics, is undervalued at current levels of under $37. IONS stock is down 11% from the levels of around $42 it was at on March 23, 2020...

Ionis Pharmaceuticals (IONS) Names Joseph Loscalzo Chairman, Allene Diaz Appointed Director

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced changes to its board of directors. Joseph Loscalzo, M.D., Ph.D., has been appointed chairman of the board and Allene M. Diaz has been appointed to the board.

SVB Leerink Boosts Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $41.00

Ionis Pharmaceuticals (NASDAQ:IONS) had its target price lifted by equities researchers at SVB Leerink from $36.00 to $41.00 in a research note issued on Friday, Benzinga reports. The firm currently has a "market perform" rating on the stock. SVB Leerink's target price points to a potential upside o…

Ionis Pharmaceuticals (NASDAQ:IONS) Upgraded at UBS Group

Ionis Pharmaceuticals (NASDAQ:IONS) was upgraded by research analysts at UBS Group from a "sell" rating to a "neutral" rating in a research report issued to clients and investors on Friday, Briefing.com reports. The firm presently has a $37.50 price objective on the stock, up from their previous pri…
Show more

Ionis Pharmaceuticals Blogs

Ionis reports second quarter 2021 financial results and recent business achievements

Key Phase 3 milestones move tofersen, eplontersen and pelacarsen closer to the market Exclusive license to Bicycle Therapeutics' technology potentially expands LICA technology capabilities Webcast today, August 4, 2021, at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Aug.

Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events

Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events Content Import Mon, 08/02/2021 - 09:31 Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recur…

Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen

Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen Content Import Thu, 07/29/2021 - 07:07 Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen July 29, 2021 at 7:05 AM EDT This release is a backfill from a News W…

Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC

- Phase 1b study of BIIB080/IONIS-MAPT Rx met primary objective of safety and tolerability - Study demonstrated durable, robust, time and dose dependent lowering of tau protein in cerebrospinal fluid CAMBRIDGE, Mass. and CARLSBAD, Calif. , July 26, 2021 /PRNewswire/ --  Biogen Inc.

Ionis to hold second quarter 2021 financial results webcast

Ionis to hold second quarter 2021 financial results webcast Content Import Wed, 07/21/2021 - 07:05 Ionis to hold second quarter 2021 financial results webcast July 21, 2021 at 7:05 AM EDT This release is a backfill from a News Wire General …

Ionis' Chief Scientific Officer C. Frank Bennett, Ph.D., receives Gabbay Award in Biotechnology and Medicine

- Award recognizes Dr. Bennett's innovative work on antisense therapy CARLSBAD, Calif. , June 14, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that Executive Vice President and Chief Scientific Officer C. Frank Bennett , Ph.D., is a co-recipient of the 23 rd
Show more

Ionis Pharmaceuticals Frequently Asked Questions

  • When was Ionis Pharmaceuticals founded?

    Ionis Pharmaceuticals was founded in 1989.

  • Who are Ionis Pharmaceuticals key executives?

    Ionis Pharmaceuticals's key executives are Brett P. Monia, Onaiza Cadoret-Manier and C. Frank Bennett.

  • How many employees does Ionis Pharmaceuticals have?

    Ionis Pharmaceuticals has 757 employees.

  • What is Ionis Pharmaceuticals revenue?

    Latest Ionis Pharmaceuticals annual revenue is $729.3 m.

  • What is Ionis Pharmaceuticals revenue per employee?

    Latest Ionis Pharmaceuticals revenue per employee is $963.4 k.

  • Who are Ionis Pharmaceuticals competitors?

    Competitors of Ionis Pharmaceuticals include Intellia Therapeutics, Ultragenyx Pharmaceutical and Bluebird Bio.

  • Where is Ionis Pharmaceuticals headquarters?

    Ionis Pharmaceuticals headquarters is located at 2855 Gazelle Ct, Carlsbad.

  • Where are Ionis Pharmaceuticals offices?

    Ionis Pharmaceuticals has an office in Carlsbad.

  • How many offices does Ionis Pharmaceuticals have?

    Ionis Pharmaceuticals has 1 office.